喘息とCOPDに使用される現在の短時間,長時間,超長時間作用のβ2-アゴニストの分子薬理学的性質の比較
Richard G W Proudman1, Jillian G Baker1,2,3
1Cell Signalling, COMPARE, School of Life Sciences, C Floor Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK.
Pharmacology research & perspectives
|September 1, 2025
まとめ
短効性,長効性,超長効性ベータアゴニストは重複する分子特性を示します. 非薬理学的要因は,喘息とCOPDの治療における臨床結果において,分子薬理学と同じくらい重要である.
科学分野:
- 薬理学について
- 呼吸器医学
- 分子生物学
背景:
- ベータアゴニストは 一世紀以上もの間 喘息の治療に使われてきました
- 最近の変化には,COPDに対する超長作用のアゴニストと,短作用のサルブタモールよりもフォルモテロール/ICSを好む新しい喘息のガイドラインが含まれています.
- ベータアゴニストの異なるクラスの in vitro 分子薬理学に関する直接比較は限られている.
研究 の 目的:
- 短効,長効,超長効のβ2アゴニストの in vitro 分子薬理を直接比較する.
- ヒトのβ2およびβ1アドレノ受容体における親和性,選択性,内在的有効性および持続時間を調査する.
- 共通のベータ2ポリモルフィズムがこれらの性質に与える影響を評価する.
主な方法:
- ラジオリガンド結合と機能研究が用いられました.
- ヒトのβ2およびβ1アドレノ受容体におけるβ2アゴニストの評価
- 4つの一般的なβ2ポリモルフィズムを安定的に発現するCHO細胞を使用した.
主要な成果:
- 長効薬と超長効薬の間で,分子特性の重複と変化が著しく観察された.
- サルメトロールとビランテロルは高ベータ2選択性 (> 1000倍),インダカテロルは中等選択性 (40倍) を示した.
- ホルモテロールとインダカテロールは最も有効で,サルメテロールは最も長い結合期間を示し,リポフィリティと相関していた.
結論:
- 臨床的に有効なベータ2アゴニストの分子薬理学的性質は幅広く変化し,長作用および超長作用のカテゴリーが著しく重複する.
- 特定の分子相互作用 (例えば,サルメトロール/ビランテロールによるエクソサイト利用) は,親和性と選択性に寄与する.
- デバイスの特性や患者のアデレンスを含む非薬理学的要因は,個々のβ2アゴニストの分子特性の重要性に匹敵する臨床結果に有意に影響を与える可能性があります.
関連する概念動画
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
377
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
377
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
449
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
449
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:17Drugs Used in Lower Respiratory Disorders: Overview
575
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
575
01:24Antiasthma Drugs: Methylxanthines
395
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
395
01:26COPD: Management Using Bronchodilators and Corticosteroids
305
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
305